Implications Involving Autoimmune Mechanisms to the PCP Receptor in Schizophrenia

  • H. D. Whitten
  • K. Y. Tsang
  • P. Arnaud
  • N. K. Khansari
  • H. H. Fudenberg

Abstract

Substantial evidence indicates that autoimmune mechanisms may either accompany or even precipitate some forms of psychoses. Such findings include: 1. Up to 50% of systemic lupus erythematosus (SLE) patients demonstrate some kind of neuropsychiatric disease; the most commom symptom (psychotic alteration in behavior or thinking) is not due to any known pre-existing psychiatric illness.1 2. The deposition of immune complexes in the choroid plexus is common in such cases and often has been shown to culminate ultimately in both DNA-anti-DNA antibody complexes in the cerebrospinal fluid (CSF)2 and lymphocytic perivascular cuffing of small blood vessels in the frontal cortex and hippocampus.1 Interestingly, although CNS involvement usually develops late in the course of SLE, it often occurs early and can appear as a sporadic disturbance of mental function.3 Thus, evidence exists supporting the concept of altered blood-brain barrier permeability accompanying immune complex disease.1,4 In fact, Rudin has suggested that every SLE patient would develop psychosis if other lethal complications were avoided.5 3. Anti-brain antibodies are commonly detected in SLE and schizophrenia. Bluestein6 reported that 78% of SLE sera contain IgM antineuronal antibody and 17% had IgG antineuronal antibody. Antibrain antibodies have been detected in the sera and sometimes the CSF of 48% of schizophrenics by Pandey and co-workers.7 Others have found 17%, 25%, 21%, 29%, 86%, and 63%8–14 depending on the sensitivity of the test utilized for antibody detection. One of the most interesting studies came from Luria and Domashneva15 in which sera (1:32 dilution) of schizophrenics demonstrated a 100% positive immunofluorescence toward mouse thymocytes in contrast to no reactivity from healthy donors. This finding was later confirmed and extended by Goldstein et al.16

Keywords

Systemic Lupus Erythematosus Systemic Lupus Erythematosus Patient Choroid Plexus Sigma Receptor Antineuronal Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    D.A.S. Compston, “Neurological Disease”, in: Immunology in Medicine Medicine, E.J. Holborow and W. Reeves, ed., Grune & Stratton, New York, N.Y. (1983).Google Scholar
  2. 2.
    R.J. Harbeck, A.A. Hoffman, S.A. Hoffman and D.W. Shucarel, CSF and and the choroid plexus during acute immune complex disease, Clin. Immunol. Immunopathol. 13: 413 (1979).CrossRefGoogle Scholar
  3. 3.
    R.T. Johnson and E.P. Richardson, The neurological manifestations of SLE, Medicine 47: 337 (1968).PubMedCrossRefGoogle Scholar
  4. 4.
    L.D. Petz, G.C. Sharp, N.R. Cooper and W.S. Irwin, Serum and CSF complement and serum autoantibodies in SLE, Medicine 50: 259 (1971).PubMedCrossRefGoogle Scholar
  5. 5.
    D.O. Rudin, The choroid plexus and system disease in mental illness. II. Systemic lupus erythematosus: a combined transport dysfunction model for schizophrenia, Biol. Psychiat. 16: 373 (1981).Google Scholar
  6. 6.
    H.G. Bluestein, Neurocytotoxic antibodies in serum of patients with with systemic lupus erythematosus, Proc. Natl. Acad. Sci. (USA) 75: 3965 (1978).CrossRefGoogle Scholar
  7. 7.
    R.S. Pandey, A.K. Gupta and U.C. Chaturvedi, Autoimmune model of schizophrenia with special reference to antibrain antibodies, Biol. Psychiat. 16: 1123 (1981).Google Scholar
  8. 8.
    R.T. Rubin, Investigation of precipitins to human brain in sera of psychotic patients, Brit. J. Psychiat. 110: 84 (1965).Google Scholar
  9. 9.
    N.I. Kuznetoza and S.F. Semenov, Detection of antibrain antibodies in the sera of patients with neuropsychiatric disorders, Zh. Neuropatol. Psikhiatr. 61: 869 (1961).Google Scholar
  10. 10.
    M. Yokoyama, E.G. Trams and R.O. Brady, Sphingolipid antibodies in animals and patients with central nervous system lesions, Proc. Soc. Exptl. Med. 111: 350 (1962).Google Scholar
  11. 11.
    R.G. Heath and I.M. Krupp, Schizophrenia as an immunologic disorder. I. Demonstration of antibrain globulins by fluorescent antibody techniques, Arch. Gen. Psychiat. 16: 1 (1967).Google Scholar
  12. 12.
    M. Stern, R. Anavi and J.P. Witz, Tissue-binding factor in schizophrenic sera: A clinical and genetic study. Biol. Psychiat. 12: 199 (1977).PubMedGoogle Scholar
  13. 13.
    R.F. Willikens,R.R. Whitaker, R.V. Anderson and D. Berven, Significance of antinuclear factors in older persons. Ann. Rheumatic Diseases 26:306 (1967).Google Scholar
  14. 14.
    N.I. Kuznetzova, “Some data concerning the immunological properties of brain mitochondria”, in: “Biological Research in Schizophrenia”, M. Vartanian, ed., Ordina Lennia, Moscow (1967).Google Scholar
  15. 15.
    E.A. Luria and I.V. Domashneva, Antibodies to thymocytes in sera of patients with schizophrenia. Proc. Natl. Acad. Sci. (USA) 71: 235 (1974).CrossRefGoogle Scholar
  16. 16.
    A.L. Goldstein, J. Rossio, G.I. Kolyeskina, L.E. Emory, J.E., Overall, G.B. Thurman and J. Hatcha, “Immunological components in schizophrenia”, in: “Perspectives in Schizophrenia Research, C. Baxter and T. Melnechuk, eds., Raven Press, N.Y. (1980).Google Scholar
  17. 17.
    R.G. Browne and W.M. Welch, Stereoselective antagonism of phencyclidine’s discriminative properties by adenosine receptor agonists, Science 217: 1157 (1982).PubMedCrossRefGoogle Scholar
  18. 18.
    R.R. Goodman, M.J. Kuhar, L. Hester and S.H. Synder, Adenosine receptors: autoradiographic evidence for their location on axon terminals of excitatory neurons, 220: 967 (1983).Google Scholar
  19. 19.
    L.L. Hsu, R.C. Smith, C. Rolstein and D.E. Leelavathei, Effects of acute and chronic PCP on neurotransmitter enzyme in rat brain, Biochem. Pharmacol. 29: 2524 (1980).Google Scholar
  20. 20.
    J.P. Vincent, J. Vignon, B. Kartalouski and C.B. Pert, “Receptor sites for phencyclidine in mammalian brain and peripheral organs”, in: “PCP: Historical and Current Perspectives”, E.F. Domino, ed., Ann Arbor, Michigan (1981).Google Scholar
  21. 21.
    R. Quirion, R.P. Hammer, M. Horkenham and C.B. Pert, Phencyclidine (angel dust/sigma “opiate” receptor): Visualization by tritium-sensitive film, Proc. Natl. Acad. Sci. U.S.A. 78: 5881 (1981).PubMedCrossRefGoogle Scholar
  22. 22.
    R.S. Zukin and S.R. Zukin, Multiple opiate receptors: Emerging concepts, Life Sciences 29: 2681 (1981).PubMedCrossRefGoogle Scholar
  23. 23.
    A.R Gintzler, R.S. Zukin and S.R. Zukin, Effects of phencyclidine and its derviatives on enteric neurons, Brit. J. Pharmacol. 75: 261 (1982).Google Scholar
  24. 24.
    R. Oswald and J.P. Changeux, Ultraviolet light-induced labeling by noncompetitive blocking of the acetylcholine receptor from Torpedo marmorata, Proc. Natl. Acad. Sci. U.S.A. 78: 3925 (1981).PubMedCrossRefGoogle Scholar
  25. 25.
    E.X. Albuquerque, L.G. Aguayo, J.E. Wannick et al., The behavioral effects of phencyclidines may be due to their blockade of potassium channels, Proc. Natl. Acad. Sci. U.S.A. 78: 7792 (1981).PubMedCrossRefGoogle Scholar
  26. 26.
    R.T. Canoso, M.E. Lewis and E.J. Yunis, Association of HLA-Bw44 with chlorpromazine-induced autoantibodies, Clin. Immunol. Immunopathol. 25: 278 (1982).CrossRefGoogle Scholar
  27. 27.
    T.J. Crow, Molecular pathology of schizophrenia: More than one disease process? Brit. Med. J. 280: 66 (1980).CrossRefGoogle Scholar
  28. 28.
    R. Rodnight, Schizophrenia: Some current neurochemical approaches, J. Neurochem. 41: 12 (1983).PubMedCrossRefGoogle Scholar
  29. 29.
    J.G. Knight, Dopamine-receptor-stimulating autoantibodies: A possible cause of schizophrenia, The Lancet iî: 1073 (1982).Google Scholar
  30. 30.
    R. Quirion, M.A. Bayorh, R.L. Zorlie and C.B. Pert, Chronic phencyclidine treatment decreases phencyclidine and dopamine receptors in rat brain, Pharmacol. Biochem. Behay. 17: 699 (1982).CrossRefGoogle Scholar
  31. 31.
    H.H. Fudenberg, H.D. Whitten, E. Merler and 0. Farmati, Is schizophrenia an anti-receptor disorder? Medical Hypothesis 12: 85 (1983).CrossRefGoogle Scholar
  32. 32.
    T.L. Lentz, T.E. Burrage, A.L. Smith, J. Crick and G.H. Tignor, Is the acetylcholine receptor a rabies-virus receptor? Science 215: 182 (1982).PubMedCrossRefGoogle Scholar
  33. 33.
    M.F. Hamilton and J.B. Winfield, T gamma cells in systemic lupus erythematosus, Arth. Rheumatol. 22: 1 (1979).Google Scholar
  34. 34.
    C. Morimoto, Loss of suppressor T-lymphocyte function in patients with systemic lupus erythematosus, Clin. Exp. Immunol. 32: 125 (1978).Google Scholar
  35. 35.
    A.S. Fauci, A.D. Steinberg, B.F. Haynes and G. Whalen, Immunoregulatory aberrations in systemic lupus erythematosus, J. Immunol. 121: 1473 (1978).PubMedGoogle Scholar
  36. 36.
    A. Sagawa and N.T. Abdou, Suppressor-cell dysfunction in systemic lupus erythematosus, J. Clin. Invest. 62: 789 (1978).PubMedCrossRefGoogle Scholar
  37. 37.
    F. Gmelig-Meyling, and T.A. Waldman, Human B cell activation in vitro: Augmentation and suppression by monocytes of the immunoglobulin production induced by various B cell stimulants, J. Immunol. 126: 529 (1981).PubMedGoogle Scholar
  38. 38.
    J. Oger, J. Szudhet, J. Antel, B.G.W. Arnason, A monoclonal antibody against human T suppressor lymphocytes binds specifically to the surface of cultured oligoendrocytes, Nature 295: 66 (1982).PubMedCrossRefGoogle Scholar
  39. 39.
    J. Wybran, T. Appelboom, J.P. Famasy and A. Govaerts, Suggestive evidence for receptors for morphine or methionine-enkephalin in normal human blood lymphocytes, J. Immunol. 123: 1068 (1983).Google Scholar
  40. 40.
    D.G. Payan, D.R. Brewster and E.F. Goetzl, Specific stimulation of human T lymphocytes by Substance P, J. Immunol. 131: 1613 (1983).PubMedGoogle Scholar
  41. 41.
    P.M. Matthews, C.J. Froehlick, W.L. Sibbitt and A.D. Edmonds, Enhancement of natural cytotoxicity by beta-endorphin, J. Immunol. 131: 1658 (1983).Google Scholar
  42. 42.
    E.D. Luby, Phencyclidine revisited: PCP research and functional psychoses, Psychopharmacol. Bull. 16: 85 (1980).Google Scholar
  43. 43.
    S.H. Synder, Phencyclidine, Nature 285: 355 (1980).CrossRefGoogle Scholar
  44. 44.
    P.H. Plotz, Autoantibodies are anti-idiotype antibodies to antiviral antibodies, Lancet 290: 824 (1983).CrossRefGoogle Scholar
  45. 45.
    C. Moroz, H. Bessler, M. Djaldetti and R.H. Stevens, Human adenosine receptor bearing lymphocytes: enumeration, characterization and distribution in peripheral blood lymphocytes, Clin. Immunol. Immunopathol. 18: 47 (1981).CrossRefGoogle Scholar
  46. 46.
    D.N. Bailey and A. Zettner, PCP binding in human serum, Res. Commun. Subst. Abuse 3: 237 (1982).Google Scholar
  47. 47.
    R. Palacios, Role of autologous rosette-forming T cells in the concanavalin A-induced supppressor cell functions, Cell. Immunol. 61: 273 (1981).Google Scholar
  48. 48.
    T. Sakane, M. Honda, Y. Taniguchi and H. Kotani, Separation of concanavalin A-induced human suppressor and helper T cells by the autologous erythrocyte rosette technique, J. Clin. Invest. 68: 447 (1981).PubMedCrossRefGoogle Scholar
  49. 49.
    N. Khansari, M. Petrini, F. Ambrogi et al., Role of autorosette forming cells in antibody synthesis in vitro: suppressive activity of ARFC in humoral immune response, Immunobiology 166: 1 (1984).PubMedCrossRefGoogle Scholar
  50. 50.
    J.H. Russell and C.B. Dobos, Accelerated 86Rb+ (K+) release from the cytotoxic T lymphocyte is a physiologic event associated with delivery of the lethal hit, J. Immunol. 131: 1138 (1983).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1986

Authors and Affiliations

  • H. D. Whitten
    • 1
  • K. Y. Tsang
    • 1
  • P. Arnaud
    • 1
  • N. K. Khansari
    • 1
  • H. H. Fudenberg
    • 1
  1. 1.Department of Basic and Clinical ImmunologyMedical University of South CarolinaCharlestonUSA

Personalised recommendations